Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sales & Earnings In Brief

This article was originally published in The Tan Sheet

Executive Summary

Schering-Plough: Consumer health care sales advanced 2 percent in the firm's fiscal 2008 second quarter to $401 million, benefiting from the performance of laxative MiraLAX, which had sales of $28 million in the period, the Kenilworth, N.J.-based company reports July 21. MiraLAX, which was launched in February 2007 as the first Rx-to-OTC switch in the laxative category in more than 30 years, has reached the same market share as Metamucil in the powder laxative category, S-P claims ("The Tan Sheet" Dec. 11, 2006, p. 17). Consumer health sales growth was offset, however, by lower sales of OTCClaritin, which was negatively impacted by the timing of shipments, a less severe allergy season and increased competition, the company notes. Net sales in the quarter advanced 54.8 percent to $4.92 billion, including sales of Organon BioSciences, which S-P purchased in November. Net income fell 19 percent to $436 million, in part reflecting acquisition costs. The firm declined to comment on future plans for cholesterol-lowering drug Vytorin following news that it failed to benefit patients with a rare heart valve disorder. S-P markets Vytorin through a joint-venture with Merck...

You may also be interested in...

ENHANCE Results Do Little To Enhance Merck’s Statin Product Outlook

The Merck/Schering-Plough combination cholesterol therapy Vytorin has failed to demonstrate significant benefit over simvastatin alone in preventing formation of arterial plaque in the ENHANCE trial

S-P Brings New Laxative Class To OTC Market Under Braintree Licensing Deal

Schering-Plough will position Braintree Laboratories' MiraLAX laxative as an effective treatment for occasional constipation without "harsh" side effects linked to other OTC laxative products

Interview With Schering-Plough CEO Fred Hassan

Fred Hassan assumed leadership of Schering-Plough in 2003 to revive a company hampered by legal, regulatory and financial difficulties. Schering was faced with a five-year FDA consent decree and the decline of its marquee prescription Claritin franchise. Hassan brought with him a reputation for successfully turning around struggling firms. He served as CEO of Pharmacia before selling the company to Pfizer in 2002. Prior to joining Pharmacia, Hassan served as executive VP-pharmaceuticals & medical products at Wyeth. Hassan discussed a number of issues facing Schering in 2005 with "The Tan Sheet" on Feb. 8.


Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts